HomeCompareGCWOF vs PFE

GCWOF vs PFE: Dividend Comparison 2026

GCWOF yields 0.86% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GCWOF wins by $2.76M in total portfolio value
10 years
GCWOF
GCWOF
● Live price
0.86%
Share price
$10.47
Annual div
$0.09
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.81M
Annual income
$2,300,691.30
Full GCWOF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — GCWOF vs PFE

📍 GCWOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGCWOFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GCWOF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GCWOF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GCWOF
Annual income on $10K today (after 15% tax)
$73.15/yr
After 10yr DRIP, annual income (after tax)
$1,955,587.60/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, GCWOF beats the other by $1,933,267.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GCWOF + PFE for your $10,000?

GCWOF: 50%PFE: 50%
100% PFE50/50100% GCWOF
Portfolio after 10yr
$1.43M
Annual income
$1,163,475.01/yr
Blended yield
81.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

GCWOF
No analyst data
Altman Z
3.7
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GCWOF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGCWOFPFE
Forward yield0.86%6.13%
Annual dividend / share$0.09$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$2.81M$49.6K
Annual income after 10y$2,300,691.30$26,258.71
Total dividends collected$2.75M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GCWOF vs PFE ($10,000, DRIP)

YearGCWOF PortfolioGCWOF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$10,872$172.11$9,153$693.39+$1.7KGCWOF
2$11,983$349.76$8,593$849.25+$3.4KGCWOF
3$13,542$720.55$8,336$1,066.78+$5.2KGCWOF
4$16,012$1,522.08$8,437$1,384.80+$7.6KGCWOF
5$20,497$3,363.93$9,013$1,875.40+$11.5KGCWOF
6$29,981$8,048.81$10,306$2,680.72+$19.7KGCWOF
7$54,085$22,005.30$12,820$4,101.38+$41.3KGCWOF
8$132,071$74,200.31$17,673$6,826.70+$114.4KGCWOF
9$479,992$338,676.45$27,543$12,591.86+$452.4KGCWOF
10$2,814,283$2,300,691.30$49,560$26,258.71+$2.76MGCWOF

GCWOF vs PFE: Complete Analysis 2026

GCWOFStock

GCC, S.A.B. de C.V., through its subsidiaries, produces, distributes, and sells gray Portland cement, ready-mix concrete, aggregates, and other building construction materials in Mexico and the United States. It offers cement; ready mix concrete, energy; building materials; and asphalt. The company also provides special products comprising Komponent, a shrinkage-compensating, expanding concrete additive; Metaforce, a reactive and consistent pozzolan that is used as an alternative for fly ash; Microsilex to be used in bridge decks and paving; Rapid Set, a solution for concrete applications; and Versabind, a cementitious that is used as filler in asphalt mixes as a replacement for lime. It distributes its products through distribution centers and independent wholesale distributors. The company was formerly known as Grupo Cementos de Chihuahua, S.A.B. de C.V. and changed its name to GCC, S.A.B. de C.V. in March 2021. GCC, S.A.B. de C.V. was founded in 1941 and is based in Chihuahua, Mexico. GCC, S.A.B. de C.V. is a subsidiary of CAMCEM, S.A. de C.V.

Full GCWOF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this GCWOF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GCWOF vs SCHDGCWOF vs JEPIGCWOF vs OGCWOF vs KOGCWOF vs MAINGCWOF vs JNJGCWOF vs MRKGCWOF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.